

**RECONCILIATION OF SHARE CAPITAL AUDIT FOR THE QUARTER ENDED 31<sup>st</sup>MARCH, 2025**  
(Regulation 76 of SEBI (Depository and Participant) Regulations, 2018)

1.	For the quarter ended	<b>March 31, 2025</b>					
2.	ISIN	<b>INE03QK01018</b>					
3.	Face Value	<b>Re. 1.00/- each</b>					
4.	Name of the Company	<b>SUVEN PHARMACEUTICALS LIMITED</b>					
5.	Registered Office Address	<b># 215 Atrium, C Wing, 8th Floor, 819-821, Andheri Kurla Road, Chakala, Andheri East, Chakala Midc, Mumbai- 400093, Maharashtra, IndiaTel: 91 22 61539999</b>					
6.	Correspondence Address	<b># 202, A-Wing, Galaxy Towers, Plot No.1, Hyderabad Knowledge City, TSIC, Raidurg, Hyderabad - 500081 Telangana, India</b>					
7.	Telephone & Fax No.	<b>Ph: 040 – 23549414/3311</b>					
8.	Email Address	<a href="mailto:investorservices@suvенpharm.com">investorservices@suvенpharm.com</a>					
9.	Names of the Stock exchanges where the Company's Securities are listed.	<b>BSE Limited National Stock Exchange of India Ltd</b>					
		Number of shares			% of Total Issued Capital		
10.	Issued Capital	<b>25,45,64,956</b>			<b>100.00%</b>		
11.	Listed Capital (exchange wise) (as per Company Records)	<b>25,45,64,956–NSE</b>			<b>100.00%</b>		
		<b>25,45,64,956–BSE</b>			<b>100.00%</b>		
12.	Held in dematerialized form in CDSL	<b>1,32,20,465</b>			<b>5.19%</b>		
13.	Held in dematerialized form in NSDL	<b>24,09,71,920</b>			<b>94.66%</b>		
14.	Physical	<b>3,72,571</b>			<b>0.15%</b>		
15.	Total No. of shares (12+13+14)	<b>25,45,64,956</b>			<b>100.00%</b>		
16.	Reasons for difference if any between (10&11, 10& 15, 11 & 15)	<b>NIL</b>					
17.	Certifying the details of changes in share capital during the quarter under consideration as per Table Below						
	Particulars*	No. of Shares	Applied or not applied for listing	Listed on Exchanges (specify names)	Whether intimated to CDSL	Whether intimated to NSDL	In-prin. Approval pending for stock exchange (Specify names)
	<b>NIL</b>	<b>NIL</b>	<b>NIL</b>	<b>NIL</b>	<b>NIL</b>	<b>NIL</b>	<b>NIL</b>

*\*Rights, Bonus, Pref. Issue, ESOPs, Amalgamation, Conversion, Buyback, Capital reduction, forfeiture, any other (Specify)*

18.	Register of members electronically updated (Y/N)	<b>Yes</b>
19.	Reference of previous quarter with regards to excess dematerialized shares, if any	<b>Nil</b>
20.	Has the Company resolved the matter mentioned in point No. 19 above in the current quarter? If not, reason, why?	<b>Not applicable</b>
21.	Mention the total no. of requests, if any, confirmed after 21 days and the total no. of requests pending beyond 21 days with reasons for delay.	<b>Nil</b>
Total No. of dematrequests		No. of requests
Confirmed after 21 days		<b>Nil</b>
Pending for more than 21 days		<b>Nil</b>
		No. of shares
		<b>Nil</b>
		Reasons for delay
		<b>Nil</b>
22.	Name, Telephone & Fax No. of Compliance Officer of the Company	<b>Kundan Kumar Jha Ph: 040 – 23549414/3311</b>
23.	Name, Address, Tel. & Fax No., Reg. No. of Auditor of the Company	<b>CS. D. Renuka Practicing Company Secretary Plot No. 143, Flat No. 301, S V Kausalya Complex, Rajeev Nagar, Hyderabad - 500045 Mobile: +91-98480 59315 Reg. No: ACS11963</b>
24.	Appointment of Common agency for share registry work, if yes (name and address)	<b>KFin Technologies Limited Selenium Tower B, Plot 31-32 Gachibowli, Financial District Nanakramguda, Hyderabad – 500032</b>
25.	Any other detail that the auditor may like to provide (e.g. BIFR Company, delisting from S.E, Company changed its name etc.)	<b>NIL</b>

Place: Hyderabad  
Date: 18/04/2025

**D. RENUKA**  
Company Secretary in Practice  
C. P. No. 3460  
ICSI Peer Review UIN: L2000TL172900  
UDIN: A011963G000141983